Compare · MRK vs PRPH
MRK vs PRPH
Side-by-side comparison of Merck & Company Inc. (MRK) and ProPhase Labs Inc. (PRPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and PRPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK carries a market cap of $361.02B.
- Over the past year, MRK is up 81.3% and PRPH is down 88.6% - MRK leads by 169.9 points.
- MRK has hit the wire 12 times in the past 4 weeks while PRPH has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 3 for PRPH).
- Company
- Merck & Company Inc.
- ProPhase Labs Inc.
- Price
- $149.54+2.20%
- $0.36-18.27%
- Market cap
- $361.02B
- -
- 1M return
- +4.02%
- +0.00%
- 1Y return
- +81.26%
- -88.65%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 3
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
ProPhase Labs Inc.
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; and offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through saliva and nasal swab methods, as well as other respiratory pathogen panel testing services, including Influenza A and B, and others. It serves consumer products companies, as well as large national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was incorporated in 1989 and is headquartered in Garden City, New York.
Latest MRK
- SEC Form 8-K filed by Merck & Company Inc.
- Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
- Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
- KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
- Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
- A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
- Amendment: SEC Form 3/A filed by Merck & Company Inc.
- Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
- Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
- SEC Form 8-K filed by Merck & Company Inc.
Latest PRPH
- SEC Form 10-Q filed by ProPhase Labs Inc.
- SEC Form NT 10-Q filed by ProPhase Labs Inc.
- ProPhase Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Amendment: SEC Form 10-Q/A filed by ProPhase Labs Inc.
- Amendment: SEC Form 10-Q/A filed by ProPhase Labs Inc.
- SEC Form 10-Q filed by ProPhase Labs Inc.
- SEC Form 10-K filed by ProPhase Labs Inc.
- SEC Form NT 10-Q filed by ProPhase Labs Inc.
- ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
- SEC Form NT 10-K filed by ProPhase Labs Inc.